Stock listing
Laekna, Inc.
Selected listing: A3EMMH · LS · EUR · DE
Laekna, Inc. (Lang & Schwarz: A3EMMH), Health Technology. Latest release Aug 11, 2026: New Drug Application for LAE002 (afuresertib) Accepted by China's…
- Ticker
- Lang & Schwarz: A3EMMH
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
Latest news from Laekna, Inc.
New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
August 10, 2026
ADA 2025 | Laekna Presented Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123
June 23, 2025
Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
March 3, 2025
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
December 10, 2024
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
November 20, 2024
Research Laekna, Inc.
Alternate listings
2105:HKEX
HK · HKD
Alternate listing for Laekna, Inc.; the primary context on this page is A3EMMH:LS.
A3EMMH:LSX
DE · EUR
Alternate listing for Laekna, Inc.; the primary context on this page is A3EMMH:LS.
4U4:FWB
DE · EUR
Alternate listing for Laekna, Inc.; the primary context on this page is A3EMMH:LS.
LAEKF:OTC
US · USD
Alternate listing for Laekna, Inc.; the primary context on this page is A3EMMH:LS.